James Hoekstra to Fibrinolytic Agents
This is a "connection" page, showing publications James Hoekstra has written about Fibrinolytic Agents.
Connection Strength
0.309
-
Lopes RD, Alexander KP, Manoukian SV, Bertrand ME, Feit F, White HD, Pollack CV, Hoekstra J, Gersh BJ, Stone GW, Ohman EM. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009 Mar 24; 53(12):1021-30.
Score: 0.080
-
Boden WE, Hoekstra J, Miller CD. ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy. Am J Emerg Med. 2008 Feb; 26(2):212-20.
Score: 0.074
-
Miller CD, Banerjee A, Mahaffey KW, Kontos MC, Fermann G, Pollack CV, Antman E, Aylward P, Goodman SG, Santos R, Ferguson JJ, Califf RM, Hoekstra JW. Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. Eur Heart J. 2007 May; 28(9):1079-84.
Score: 0.070
-
Cohen M, Mahaffey KW, Pieper K, Pollack CV, Antman EM, Hoekstra J, Goodman SG, Langer A, Col JJ, White HD, Califf RM, Ferguson JJ. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2006 Oct 03; 48(7):1346-54.
Score: 0.067
-
Cohen M, Hoekstra J, Giugliano R, Granger CB, Gurbel PA, Hollander JE, Manoukian SV, Pollack CV, Saucedo JF. Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. J Interv Cardiol. 2008 Aug; 21(4):283-99.
Score: 0.019